Dashboard
1
The company has declared Positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY 1,556.97 MM
- NET SALES(HY) At CNY 4,871.59 MM has Grown at 20.48%
- NET PROFIT(HY) Higher at CNY 828.45 MM
2
With ROE of 6.76%, it has a very attractive valuation with a 0.96 Price to Book Value
3
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 18,902 Million (Large Cap)
14.00
NA
0.38%
-0.25
7.10%
1.04
Revenue and Profits:
Net Sales:
2,511 Million
(Quarterly Results - Sep 2025)
Net Profit:
225 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.65%
0%
7.65%
6 Months
9.7%
0%
9.7%
1 Year
52.44%
0%
52.44%
2 Years
96.64%
0%
96.64%
3 Years
62.78%
0%
62.78%
4 Years
-5.77%
0%
-5.77%
5 Years
-65.13%
0%
-65.13%
Intco Medical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.27%
EBIT Growth (5y)
-16.20%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.29
Tax Ratio
5.89%
Dividend Payout Ratio
6.65%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
55.32%
ROE (avg)
23.59%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
0.96
EV to EBIT
12.73
EV to EBITDA
6.47
EV to Capital Employed
0.95
EV to Sales
1.29
PEG Ratio
0.11
Dividend Yield
0.46%
ROCE (Latest)
7.46%
ROE (Latest)
6.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
2,511.30
2,419.50
3.79%
Operating Profit (PBDIT) excl Other Income
199.40
484.30
-58.83%
Interest
114.70
94.80
20.99%
Exceptional Items
16.80
156.00
-89.23%
Consolidate Net Profit
225.00
365.30
-38.41%
Operating Profit Margin (Excl OI)
79.40%
101.20%
-2.18%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 3.79% vs -2.98% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -38.41% vs 1.08% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
9,509.00
6,851.40
38.79%
Operating Profit (PBDIT) excl Other Income
1,751.40
552.60
216.94%
Interest
322.20
135.70
137.44%
Exceptional Items
245.80
175.90
39.74%
Consolidate Net Profit
1,491.70
388.10
284.36%
Operating Profit Margin (Excl OI)
93.30%
-25.00%
11.83%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 38.79% vs 4.47% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 284.36% vs -39.29% in Dec 2023
About Intco Medical Technology Co., Ltd. 
Intco Medical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






